MATINAS BIOPHARMA HOLDINGS I (MTNB) Fundamental Analysis & Valuation

NYSEARCA:MTNB • US5768103039

Current stock price

0.6324 USD
-0.01 (-1.63%)
Last:

This MTNB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MTNB Profitability Analysis

1.1 Basic Checks

  • MTNB had negative earnings in the past year.
  • MTNB had a negative operating cash flow in the past year.
  • MTNB had negative earnings in each of the past 5 years.
  • MTNB had a negative operating cash flow in each of the past 5 years.
MTNB Yearly Net Income VS EBIT VS OCF VS FCFMTNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of MTNB (-212.28%) is worse than 89.19% of its industry peers.
  • With a Return On Equity value of -315.97%, MTNB is not doing good in the industry: 73.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -212.28%
ROE -315.97%
ROIC N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
MTNB Yearly ROA, ROE, ROICMTNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MTNB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTNB Yearly Profit, Operating, Gross MarginsMTNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MTNB Health Analysis

2.1 Basic Checks

  • MTNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MTNB has been increased compared to 1 year ago.
  • Compared to 5 years ago, MTNB has less shares outstanding
  • The debt/assets ratio for MTNB is higher compared to a year ago.
MTNB Yearly Shares OutstandingMTNB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
MTNB Yearly Total Debt VS Total AssetsMTNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • MTNB has an Altman-Z score of -29.92. This is a bad value and indicates that MTNB is not financially healthy and even has some risk of bankruptcy.
  • MTNB has a Altman-Z score of -29.92. This is amonst the worse of the industry: MTNB underperforms 88.03% of its industry peers.
  • MTNB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • MTNB's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. MTNB outperforms 50.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.92
ROIC/WACCN/A
WACC8.89%
MTNB Yearly LT Debt VS Equity VS FCFMTNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • MTNB has a Current Ratio of 4.07. This indicates that MTNB is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 4.07, MTNB perfoms like the industry average, outperforming 48.46% of the companies in the same industry.
  • A Quick Ratio of 4.07 indicates that MTNB has no problem at all paying its short term obligations.
  • The Quick ratio of MTNB (4.07) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07
MTNB Yearly Current Assets VS Current LiabilitesMTNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MTNB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.18% over the past year.
  • MTNB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MTNB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.54% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTNB Yearly Revenue VS EstimatesMTNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 200M 400M 600M
MTNB Yearly EPS VS EstimatesMTNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 40 60

More info and screens

Find the best growth stocksShow best growing peers

1

4. MTNB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MTNB. In the last year negative earnings were reported.
  • Also next year MTNB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTNB Price Earnings VS Forward Price EarningsMTNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTNB Per share dataMTNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • MTNB's earnings are expected to grow with 30.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.59%
EPS Next 3Y30.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MTNB Dividend Analysis

5.1 Amount

  • No dividends for MTNB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MTNB Fundamentals: All Metrics, Ratios and Statistics

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (3/16/2026, 3:54:20 PM)

0.6324

-0.01 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)04-13
Inst Owners7.09%
Inst Owner Change34.04%
Ins Owners8.67%
Ins Owner Change0%
Market Cap4.05M
Revenue(TTM)N/A
Net Income(TTM)-24.25M
Analysts45.71
Price TargetN/A
Short Float %0.09%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-4.17
EYN/A
EPS(NY)-5.1
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0
BVpS1.2
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -212.28%
ROE -315.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z -29.92
F-Score3
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.09%
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.01%
OCF growth 3YN/A
OCF growth 5YN/A

MATINAS BIOPHARMA HOLDINGS I / MTNB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MATINAS BIOPHARMA HOLDINGS I?

ChartMill assigns a fundamental rating of 1 / 10 to MTNB.


Can you provide the valuation status for MATINAS BIOPHARMA HOLDINGS I?

ChartMill assigns a valuation rating of 1 / 10 to MATINAS BIOPHARMA HOLDINGS I (MTNB). This can be considered as Overvalued.


Can you provide the profitability details for MATINAS BIOPHARMA HOLDINGS I?

MATINAS BIOPHARMA HOLDINGS I (MTNB) has a profitability rating of 0 / 10.


Can you provide the financial health for MTNB stock?

The financial health rating of MATINAS BIOPHARMA HOLDINGS I (MTNB) is 3 / 10.


What is the earnings growth outlook for MATINAS BIOPHARMA HOLDINGS I?

The Earnings per Share (EPS) of MATINAS BIOPHARMA HOLDINGS I (MTNB) is expected to grow by 63.31% in the next year.